Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis

NCT01063803 is registered in ClinicalTrials.gov with Ablynx, a Sanofi company as lead sponsor.

NCT NCT01063803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01063803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis
Lead sponsor
Ablynx, a Sanofi company
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
February 29, 2012
Enrollment
266 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis